8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – January 11, 2012

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Item 7.01. Regulation FD Disclosure

On January 11, 2012, our management will present at the CJS Securities 12th Annual “New Ideas for the New Year” Investor Conference in New York, New York at 8:00 AM ET.

A copy of the Company’s presentation materials from the conference will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01.  Financial Statements and Exhibits

(d)	Exhibits
	Exhibit 99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III, Vice President, General

Counsel and Secretary

January 11, 2012

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

4

EX-99.1

WEST PHARMACEUTICAL SERVICES, INC.

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

© 2012 by West Pharmaceutical Services, Inc., Lionville, PA.

All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.

CJS Securities “New Ideas for the New Year”
Conference

New York, NY

January 11, 2012

Safe Harbor Statement

2

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995

This presentation and any accompanying management commentary contain “forward-looking statements”
as that term is defined in the Private Securities Litigation Reform Act of 1995.Such statements include,
but are not limited to statements about expected financial results for 2011 and future years.

Each of these estimates is based on preliminary information, and actual results could differ from these
preliminary estimates.We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.

Non-GAAP Financial Measures

Certain financial measures included in these presentation materials, and which may be referred to in
management’s discussion of the Company’s results and outlook, are Non-GAAP (Generally Accepted
Accounting Principles) financial measures. Non-GAAP financial measures should not be considered in
isolation or as an alternative to such measures determined in accordance with GAAP.

West is a globally diversified developer and manufacturer of components and
assembled systems for the packaging and delivery of injectable drugs, diagnostic
systems, and consumer products.

On average, approximately 100 million components manufactured by West and
our Global Partners are used to enhance the quality of healthcare worldwide
everyday.

Global Partners with Daikyo Seiko, Ltd. and West Pharmaceutical services Mexico, S.A. de C.V.

A Diverse, Stable Customer Base
(representative healthcare customers)

PHARMACEUTICAL / BIOTECHNOLOGY

6

GENERIC

MEDICAL DEVICE

Packaging Segment Overview

5

$840-$860

2011 Revenue Estimate

($ millions)

Packaging Systems

•Market leader

•Strong recurring revenue base

•Global manufacturing

•Steady growth in base

•Expected growth will be driven
by: added value per unit sold;
geographic expansion; and
growth in key therapeutic
segments

6

Value-Added Product StrategyStandardHigh-Value
ProductsProducts

Revenue Opportunity ($ per unit)

Plungers and
sleeve stoppers

Stoppers

Seals

RU seals

Westar® RU

Delivery Systems Segment Overview

7

$340-$350

•Customer owned IP

•Project management

•Automated assembly

•Regulated products

•Proprietary Product
Development applies those
capabilities to:

•West-owned IP

•Multiple product platforms

focused on unmet delivery
needs for biologics

8

Revenue per-unit

Consumer product
manufacturing

Medical
device
manufacturing

Mix2Vial®

CZ vials

CZ Syringes

ConfiDose®

Effect of Increasing Proprietary Device Sales
Contract ManufacturingProprietary Devices
Products

SmartDose™

•Company: Demographics, increasing prevalence of chronic disease,
increasing use of biologics to treat those diseases, better access to
healthcare

Growth Drivers Intact

9

•Packaging Systems Segment –Growth in emerging markets –Escalating regulatory and
quality demands •Delivery Systems Segment –Growth in combination
products that promote safety,
dosing accuracy, ease of use,
and deliver cost savings and
product differentiation –Increasing awareness of
glass quality issues –Adding plants: China, India –Expanding WestStar,
Envision capacity, introducing
NovoPure –SmartDose –Confidose –Reconstitution products –Safety syringes –Daikyo Crystal Zenith
products

Category	Key Customers	Projected Growth
Diabetes		> 10 %
Oncology		> 10 %
Vaccines		> 10 %
Autoimmune		>8%
Generics		>10%

IMS April 2010 Report; Business Insights 2009; GBI Research 2009

10

Therapeutic Category Growth Drivers

Recent Highlights

•First nine months of 2011:

–Sales increased 4.5%, excluding currency

–Gross and operating margin compressed by material costs, currency

–Implemented mitigating surcharge mid-year

•Updated long-term financial targets in Q3 2011 release & analyst call

•4th Quarter, Full-Year 2011 results:Release date February 16, 2012

•China rubber facility under construction

•India land lease finalized

•Demand for contract manufacturing services better than 2010

•Vetter collaboration announced for CZ filling capacity

•Glass packaging compatibility issues generating strong interest in
alternative packaging materials, especially for biologics and other
high value drugs

11

Faster Growth of High-Value ProductsPharmaceutical Packaging Systems

12

Major Influences on Gross Margin

Factors Pricing Unit Volume Sales mix Lean mfg. savings Raw material costs Labor costs Raw Material Costs Comprise approximately 1/3rd of COGS Materials include: Synthetic elastomer and
polymer and film (petroleum based),
aluminum, natural rubber Commodity and currency volatility Mitigating factors: Cost: ØContractual terms for synthetic elastomers
limit impact of short-term oil price changes
and defer the impact of persistent changes ØHedging Revenue: ØContracted sales price escalators ØMaterial surcharges on other sales

13

2012 Outlook and Challenges

•Expect 4%-6% revenue growth in 2012, excluding currency

–Will provide more detailed expectations on February analyst call

•Pharmaceutical and Device markets:

–New product pipelines showing signs of strength

–Patent cliff front and center

–Shift to large molecule products continues

–Global shift in product sourcing (e.g., India generic growth)

–More demanding regulatory environment

•Continuing Fx and commodity price volatility

–Euro, European growth and sovereign debt

–Oil and regional political, civil and military turmoil

–Less predictable demand

14

15

Pharmaceutical Packaging Systems

Pharmaceutical Delivery Systems

•Strong competitive position

•Stability with growth potential

•New products well positioned to
meet future market needs

•Financial strength to invest

•FY 2011 Year End Call February
16 at 9:00AM

Summary

WEST PHARMACEUTICAL SERVICES, INC.

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

CJS Securities “New Ideas for the New Year”
Conference

New York, NY

January 11, 2012